Shares of biopharmaceutical company Sage Therapeutics, Inc. (SAGE) are down 15 percent on Tuesday's trading. The company, however, cited positive results related to its experimental Phase 3 depression drug Zuranolone.
The company, in association with Biogen Inc. (BIIB) had conducted the WATERFALL study on patients with Major Depression Disorder or MDD. Around 543 participants were given the once-daily oral drug Zuranolone over a period of two weeks as part of the study. Sage said that the drug has met its primary endpoint, as it showed "statistically significant improvement" in symptoms compared with placebo.
The stock is now trading at $61.87, down $10.99 or 15% on the NASDAQ.
SAGE has traded between $37.22 and $98.39 during the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.